کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5123762 1487580 2017 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی غدد درون ریز، دیابت و متابولیسم
پیش نمایش صفحه اول مقاله
Short term monotherapy with exenatide is superior to metformin in weight loss, improving insulin resistance and inflammation in Chinese overweight/obese PCOS women
چکیده انگلیسی


- To evaluate the efficacy of exenatide in Chinese women.
- Exenatide is superior to metformin in weight loss, improving insulin resistance and reducing inflammation.
- Exenatide is similar in improving hyperandrogenism as metformin.
- EXE treatment is safe in PCOS women.

AimsTo evaluate the efficacy of exenatide on weight loss, insulin resistance, menstrual periods, metabolic profiles, inflammatory markers, and safety compared with metformin in Chinese overweight/obese patients with polycystic ovary syndrome.MethodsEighty-two overweight/obese (OW/OB) patients with PCOS were randomly assigned to the exenatide group (10 μg BID sc, n = 41) or metformin group (1000 mg BID po, n = 41) for 12 weeks. The main primary outcomes was mean change in body weight.ResultsSixty-three patients completed the study (31 cases in the EXE group and 32 cases in the MET group). EXE treatment was superior to MET treatment in weight loss (P = 0.009), with EXE leading to a significant mean loss of 3.1 ± 0.2 kg (P < 0.001) and MET leading to a significant mean loss of 1.2 ± 0.3 kg (P < 0.001). There was a significantly greater effect of EXE compared to metformin with respect to 2hINS, HOMA-IR, INSAUC and ISI (P < 0.001, P = 0.004, P < 0.001, P < 0.021, respectively), with both treatments leading to significant decreases in 2hINS, HOMA-IR and INSAUC (P < 0.001, P < 0.001, P < 0.001, respectively); and a significant increase in ISI (P < 0.001). FAI decreased while SHBG increased significantly with both treatments (P = 0.022, P < 0.001, respectively) with no significant difference between two groups (P > 0.05). EXE treatment was superior to MET treatment in reducing hsCRP (P = 0.016) with both treatments leading to a significant increase (P < 0.001). Menstrual periods, mFG score and Rosenfield score were not significantly different before and after treatment for either group (P > 0.05).ConclusionsShort-term exenatide treatment possesses a greater efficacy in terms of weight loss, improving insulin resistance and reducing inflammation than metformin. Large-sample and long-term clinical trials, however, are needed to assess exenatide's efficacy and safety in OW/OB women with PCOS.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Obesity Medicine - Volume 7, September 2017, Pages 15-20
نویسندگان
, , , , , , , , ,